about
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repairHeparin: Past, Present, and FutureNew Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.New parenteral anticoagulants in development.Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosisFondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation.Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.Comparative study of the effect of rivaroxaban and fondaparinux on monocyte's coagulant activity and cytokine release.Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery.Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.Recent developments in the use of oral anticoagulants.New antithrombotic drugs.Developments in factor Xa inhibitors for the treatment of thromboembolic disorders.Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?Alternatives to warfarin--the next generation of anticoagulants.Blood coagulation factor Xa as an emerging drug target.The discovery and development of rivaroxaban.Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants.Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves.New oral anticoagulants: a view from the laboratory.Reversal of antithrombotic agents.The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.A novel coagulation inhibitor from Schistosoma japonicum.Oral factor Xa inhibitors for the long-term management of ACS.Crystal structure of (S)-5-chloro-N-({2-oxo-3-[4-(3-oxomorpholin-4-yl)phen-yl]oxazolidin-5-yl}meth-yl)thio-phene-2-carboxamide.A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery.Pharmacological properties of betrixaban.A Novel Synthesis of the Oxazolidinone Antithrombotic Agent RivaroxabanPlatelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis
P2860
Q24187415-B8004455-A09D-443F-9113-3D2478E8B285Q26744227-C96B899A-8651-49F1-8871-2F15F9CD9825Q26765488-B00FE4AF-45B5-4ECF-9963-810586DA21B4Q30595943-868CEC1B-153D-4150-94B0-8D9550AEB2EBQ33392647-2F1585F2-C50A-4046-950F-EB7F01F2B241Q33397684-769F38F3-1D1C-4444-AB00-4671B8ABD6B7Q33413002-BAA666AA-00CD-42A6-BF1A-AFB4C3D60609Q34551073-74C6CE83-F203-4F70-9495-0715BC0DFDABQ34615829-BCB3C108-BDF6-4972-98A9-A12FEB05F8C2Q34981567-7810F9FC-4FC9-4D8F-98FB-43E95A554F12Q35536242-0D21B401-EF5A-4203-9193-672BC0553F4AQ36129629-1FA20373-A1A8-4507-B0DE-13FBFD9EE355Q37369329-935FAB14-17C0-4CC9-ABBB-2BE61DA446E1Q37428883-4618891E-6BF5-4B38-B066-918A6DA7C5BBQ37528463-533F78A6-092B-4059-8899-1AE31DBB5A8CQ37530424-368DC594-281B-41E4-861C-CF3BF8CC6F7EQ37646551-3D9E9B56-B828-43F6-BE80-CFD6F3C7A852Q37721619-AB614475-9590-4FE5-A9F0-C850C6963EF2Q37772227-9CE642B4-CB49-41EC-BEC2-47C6C35A9B18Q37830708-271B9484-FD6E-4A16-B762-E6029887E86DQ37857332-13A4D490-8424-4399-AFD0-45659106DBDEQ37907319-41922689-0258-4AEE-A30F-D0AC4E92B6C4Q37955199-27D2EE32-3034-4B9F-8DFD-87F54059846FQ37990454-1AC434E4-BE96-49B2-92B2-9FD8D4519B2DQ37992582-7466DF67-A602-46CC-9FB0-036D204E27F6Q37998377-6453F1F0-EDEA-4112-9FC9-614AF21FFE02Q38015427-7A822613-0813-433E-B4A2-D1DD98A2AB63Q38627495-6CB7DA75-6B2E-4362-8277-4D3CD823008AQ39941768-6C0D6018-0B3D-4C43-AE47-5A03BF525004Q40954258-B8EC8515-6076-4AB5-9913-516C376CCFD2Q43594298-4EC30845-1D0B-4969-9B2A-AC01B15224F8Q49730911-6C82914B-DDCC-40F5-8F80-2D314F3AA859Q53335452-13018B7A-255E-4720-9F7A-D83667A5694FQ55442570-D58749D7-E001-4515-9C3A-DB653D74D7E4Q57310726-A1C94AD7-9CE6-4213-AE80-3E9211CCD829Q58792339-F248FC0F-5905-4584-9B87-7FCD5CEB7FBA
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Factor Xa or thrombin: is factor Xa a better target?
@ast
Factor Xa or thrombin: is factor Xa a better target?
@en
Factor Xa or thrombin: is factor Xa a better target?
@nl
type
label
Factor Xa or thrombin: is factor Xa a better target?
@ast
Factor Xa or thrombin: is factor Xa a better target?
@en
Factor Xa or thrombin: is factor Xa a better target?
@nl
prefLabel
Factor Xa or thrombin: is factor Xa a better target?
@ast
Factor Xa or thrombin: is factor Xa a better target?
@en
Factor Xa or thrombin: is factor Xa a better target?
@nl
P1476
Factor Xa or thrombin: is factor Xa a better target?
@en
P2093
P356
10.1111/J.1538-7836.2007.02473.X
P478
P577
2007-07-01T00:00:00Z